GlassScriptPhysician profile
Kathi L Price
NPI 1477656023
$4,359.00
in general payments reported to CMS, 2019-2025
22 companies · $830 in 2025
The $830 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $897 · 2022: $1,032 · 2023: $1,021 · 2024: $579 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,032.73 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $957.82 | 2021-2025 | |
| Novo Nordisk INC | $882.79 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $381.50 | 2021-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $259.99 | 2024-2025 | Caplyta |
| Gilead Sciences, INC. | $151.04 | 2025 | Epclusa |
| Lilly USA, LLC | $103.56 | 2021-2023 | Mounjaro, Trulicity, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.78 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $85.84 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.53 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $47.50 | 2021-2024 | Trintellix |
| Amgen INC. | $45.14 | 2024 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $33.15 | 2021 | |
| Pfizer INC. | $30.74 | 2023 | |
| Glaxosmithkline, LLC. | $28.17 | 2022-2024 | Trelegy Ellipta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.12 | 2023 | Gemtesa |
| Exact Sciences Corporation | $23.42 | 2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $23.29 | 2023 | Veozah |
| Axsome Therapeutics, INC. | $19.90 | 2024 | Auvelity |
| Scynexis, INC. | $19.07 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.64 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $15.28 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathi Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.